Abstract: Compounds of the formula wherein the substituents are as defined in the specification which are useful for the treatment of pain.

Abstract: The invention concerns the use of zinc derivatives of general formula (I) wherein: L1 represents a group of formula: —E14(R14)(R?14)(R?14), —E15(R15) (R?15) or —E16(R16); E is an atom of group 15; L2 and L3 independently represent a group of formula: —E14(R14)(R?14)(R?14), —E15(R15)(R?15) or —E16(R16), or together form a chain of formula —L?2—A—L?3—; A represents a saturated or unsaturated chain comprising one, two or three elements of group 14; L?2 and L?3 independently represent a group of formula —E14(R14)(R?14) —E15(R15) or —E16—; E14 is an element of group 14; E15 is an element of group 15; E16 is an element of group 16; R14, R?14, R?14, R15, R?15 and R16 represent various groups, as (co) polymerisation catalysts of cyclic esters

Abstract: A method of modulating, sodium channels in warm-blooded animals in need thereof by administering a compound of the formula Wherein the substituents are defined as in the specification and compounds of the formula wherein the substituents are as defined in the specification.

Abstract: A method of treating pain in a warm-blooded animal comprising administering to anwarm-blooded animal in need thereof an amount of a compound of the formula wherein the substituents are defined in accordance with the disclosure.

Abstract: A subject of the present invention is new compounds having a lanthanide and having a tridentate ligand, a process for their preparation and their use in particular as polymerization catalysts.

Abstract: The invention relates to a method for preparing polyesters A containing several mid-chain free acid functions by ring-opening polymerisation in the presence of a chain initiator: the benzyl diester of the tartaric acid, the phenyl radical of which is optionally substituted. A: aliphatic based on cyclic esters such as lactides and glycolides.

Abstract: A method of treating proliferative diseases in warm-blooded animals comprising administering to warm-blooded animals in need thereof an amount of at least one compound selected from the group consisting of mikanolide and dihydromikanolide sufficient to treat said disease.

Abstract: The use of stannylenes and germylenes of general formula (I) wherein: M represents a tin or geranium atom; L1 and L2 independently represent a group of formula: -E14(R14) (R?14) (R?14), -E15(R15) (R?15) or -E16(R16)) or together form a chain of formula -L?1-A- L?2; A represents a saturated or unsaturated chain comprising one, two or three elements of group 14; L?1 and L?2, represent, independently, a group of formula: -E14(R14) (R?14)-, E15(R15)- or -E16-; E14 is an element of group 14; E15 is an element of group 15; E16 is an element of group 16; R14, R?14, R?14, R15, R?15 and R16 represent variable groups as polymerization catalysts of heterocycles.

Abstract: A process for the preparation of an extract of Ginkgo biloba leaves, comprising i. extraction of the dried fragments of Ginkgo biloba leaves in ethanol containing a maximum of 20% by weight of water; ii. concentration of the extract under reduced pressure in the presence of an aqueous solution of sodium chloride and elimination of the dark oil from the remainder of the clear solution; iii. washing of the residual aqueous solution by liquid-liquid extraction with n-hexane, n-heptane or cyclohexane, iv. liquid-liquid extraction of the aqueous phase washed with ethyl acetate; and v. washing of the ethyl acetate phase obtained in stage iv with a sodium chloride solution followed by evaporation to dryness of the washed ethyl acetate phase and use of the resulting extract to treat cerebral and peripheral vascular disorders and neurodegenerative diseases.

Abstract: The invention concerns a product inhibiting transduction of G heterotrimeric protein signals combined with another anti-cancer agent, in particular farnesyltransferase inhibitors, taxol or gemcitabin, for simultaneous, separate or prolonged therapeutic use in cancer treatment.

Abstract: A method of treating cholera or travel diarrhea in a patient in need thereof by an effective amount of a compound of the formula wherein the substrates are defined in the specification or its non-toxic, pharmaceutically acceptable salts.

Abstract: Compounds of the formula wherein R1 is alkyl and R2 is alkenyl, alkynyl, allenyl or cyanoalkyl, n is 0 or 1, k is an integer from 1 to 3, X is —(CH2)m— and m is 0 or 1; and pharmaceutical salts thereof useful for inhibiting NO synthases and/or monoamine oxydases.

Abstract: The invention concerns the use of pyrido-thieno-triazolo-diazepins for preparing a medicine for treating pathological conditions or diseases involving one of the growth hormone release inhibiting factor receptors. The invention also concerns novel pyrido-thieno-triazolo-diazepins and therapeutic compositions containing them.

Abstract: The invention relates to cross-linked copolymers based on non cross-linked polycarboxylic copolymers, said non cross-linked copolymers containing at least one polysaccharide. The invention also relates to a process for the preparation of these copolymers and their use in particular as a support in pharmaceutical compositions.

Abstract: The invention relates in particular to the compounds of general formula in which R1, R2, R3, R4, R5, R6 represent various radicals; their use as medicaments and pharmaceutical compositions containing them. These compounds are particularly useful for the treatment of cancer.

Abstract: The invention relates to a pre-filled injection device for injecting a liquid or semisolid composition into a subject, said injection device comprising: a housing (1) containing at its distal end the liquid or semisolid composition (2), a plunger (3) arranged to slide within the housing (1) to which is affixed a plunger stick (7) extending longitudinally from the plunger to the outside of the housing (1), a hollow needle (4) affixed to the distal end of the housing (1), said needle (4) connecting the interior part of the housing (1) with the outside where it extends longitudinally, and an airtight needle shield (5) which protects said needle (4), characterized in that said device further comprises a cap (6) designed to fit around the housing's proximal end and to fully cover said plunger stick (7), said cap (6) both preventing its accidental pushing or breakage before use and being adapted to receive the injection device once the injection into the subject has been carried out.

Abstract: Compounds of formula wherein the substituents are as defined in the specification which compounds are useful for inhibiting the activity of NO-synthase enzymes.

Abstract: The invention concerns novel mikanolide derivatives, their preparation method and their therapeutic uses, in particular as anti-cancer and anti-viral agents.

Abstract: The invention concerns a product comprising at least a NO synthase inhibiting substance associated with at least a phospholipase A2 inhibiting substance, separately or combined, for simultaneous therapeutic use, separately or spread over time for treating pathologies in which nitrogen monoxide and/or phospholipases A2 are involved. The invention also concerns a pharmaceutical composition comprising, an active principle, at least a NO synthase inhibiting substance and at least a phospholipase A2 inhibiting substance, and optionally a pharmaceutically acceptable.

Abstract: The invention concerns a product comprising at least an inhibitor of heterotrimeric G protein signal transduction, associated with at least another anti-hypertensive agent, in particular calcium channel blockers and conversion enzyme inhibitors, for simultaneous, separate or prolonged therapeutic use, in the treatment of hypertension.